Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry

MI (Maren) Blonk, BC van der Nagel, Liesbeth Smit, RAA Mathot

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Scopus)


A sensitive and specific method using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the determination of levetiracetam (LEV) in plasma of neonates. A plasma aliquot of 50 mu l was deproteinized by addition of 500 mu l methanol which contained 5 mu g/ml UCB 17025 as an internal standard. After centrifugation, 50 mu l of supernatant was diluted with 1000 mu l of 0.1 % formic acid-10 mM ammonium formate in water (pH 3.5) (mobile phase solution A) and 2 mu l was injected onto the UPLC-system. Compounds were separated on a Acquity UPLC BEH C-18 2.1 mm x 100 mm column using gradient elution with mobile phase solution A and 0.1% formic acid in methanol (mobile phase solution B) with a flow rate of 0.4 ml/min and a total runtime of 4.0 min. LEV and the internal standard were detected using positive ion electrospray ionization followed by tandem mass spectrometry (ESI-MS/MS). The assay allowed quantification of LEV plasma concentrations in the range from 0.5 mu g/ml to 150 mu g/ml. Inter-assay inaccuracy was within +/- 2.7% and inter-assay precision was less than 4.5%. Matrix effects were minor: the recovery of LEV was between 97.7% and 100%. The developed method required minimal sample preparation and less plasma sample volume compared to earlier published LC-MS/MS methods. The method was successfully applied in a clinical pharmacokinetic study in which neonates received intravenous administrations of LEV for the treatment of neonatal seizures. (C) 2010 Elsevier B.V. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)675-681
Number of pages7
JournalJournal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences
Issue number7-8
Publication statusPublished - 2010

Research programs

  • EMC OR-01-34-01

Cite this